These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9522840)

  • 61. Current pharmacotherapies for Alzheimer's disease.
    Knopman DS
    Geriatrics; 1998 Sep; 53 Suppl 1():S31-4. PubMed ID: 9745634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Alzheimer's disease].
    Jedidi H; Jedidi Z; Salmon E
    Rev Med Liege; 2010 Mar; 65(3):163-8. PubMed ID: 20411822
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
    Visser PJ; Scheltens P; Verhey FR
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1348-54. PubMed ID: 16170074
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents.
    Yang J; Zhang P; Hu Y; Liu T; Sun J; Wang X
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):651-656. PubMed ID: 30746966
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients?
    Ames D; Ritchie C
    Int Psychogeriatr; 2007 Feb; 19(1):1-8. PubMed ID: 17310512
    [No Abstract]   [Full Text] [Related]  

  • 66. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical inquiries. Do patients at high risk of Alzheimer's disease benefit from early treatment?
    Holt J; Stiltner L; Wallace R; Raetz J
    J Fam Pract; 2009 Jun; 58(6):320-2. PubMed ID: 19508846
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New therapies. New Alzheimer's treatments that may ease the mind.
    Helmuth L
    Science; 2002 Aug; 297(5585):1260-2. PubMed ID: 12193764
    [No Abstract]   [Full Text] [Related]  

  • 70. [Is there a treatment for Alzheimer's disease?].
    Joray S; Ghika J; von Gunten A; Büla C; Gold G; Assal F
    Rev Med Suisse; 2005 May; 1(18):1201-2, 1205-6, 1208. PubMed ID: 15977708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
    Xu R; Xiao G; Li Y; Liu H; Song Q; Zhang X; Yang Z; Zheng Y; Tan Z; Deng Y
    Bioorg Med Chem; 2018 May; 26(8):1885-1895. PubMed ID: 29500132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The pharmacological management of cognitive dysfunction in Alzheimer's disease.
    Vandewoude MF
    Acta Clin Belg; 1999 Oct; 54(5):306-11. PubMed ID: 10555391
    [No Abstract]   [Full Text] [Related]  

  • 74. Natural antioxidants in Alzheimer's disease.
    Mancuso C; Bates TE; Butterfield DA; Calafato S; Cornelius C; De Lorenzo A; Dinkova Kostova AT; Calabrese V
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1921-31. PubMed ID: 18042001
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment options for Alzheimer's disease.
    Dinsmore ST
    J Am Osteopath Assoc; 1999 Sep; 99(9 Suppl):S6-8. PubMed ID: 10730506
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 79. Alzheimer's disease: current knowledge, management and research.
    Gauthier S; Panisset M; Nalbantoglu J; Poirier J
    CMAJ; 1997 Oct; 157(8):1047-52. PubMed ID: 9347775
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Therapeutic agents for Alzheimer's disease].
    Honma A
    Nihon Naika Gakkai Zasshi; 1998 Jan; 87(1):169-74. PubMed ID: 9513562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.